AVANOS MEDICAL, INC. (AVNS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-05

Key Insights

Avanos Medical announced Q1 2026 earnings results on May 5, 2026, providing investors with operational performance data for the three months ended March 31, 2026.
The 8-K filing is a standard earnings announcement with no material events, executive changes, or significant corporate actions disclosed beyond the quarterly financial results.
The press release content is furnished but not filed, meaning it is not subject to Section 18 liability under the Exchange Act and will not be incorporated into future regulatory filings unless explicitly stated.

Want the newest filings?

This analysis covers the filing from 2026-05-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-14

Avanos Medical has agreed to be acquired for $25 per share in cash, representing a premium over the current stock price.
The merger agreement includes provisions for the cancellation and cash-out of outstanding equity awards held by Avanos employees.
The merger is subject to customary closing conditions, including approval by a majority of Avanos shareholders and regulatory clearance.

Filed: 2026-03-12

The company has increased the target value of the annual long-term incentive grant for its CEO, David C. Pacitti, from $5,000,000 to $5,500,000, effective in 2026. This suggests the company is investing more in its leadership and aligning executive compensation with long-term performance.
The filing does not mention any other significant changes or events, indicating the company is operating in a stable manner without any major disruptions or announcements.
Investors should monitor the company's financial performance and any future changes in executive compensation or leadership to assess the overall health and strategic direction of the business.

Filed: 2026-02-26

Avanos Medical announced that it has entered into a letter agreement with Bradley L. Radoff and The Radoff Family Foundation, which includes the nomination of two new independent directors to the Board.
The agreement includes withdrawal of Radoff's previously announced director nomination, as well as standstill and voting commitments from the Radoff Parties.
The nomination of the two new independent directors could signal a positive development in shareholder engagement and potential board refreshment at Avanos.

Filed: 2026-02-24

Avanos Medical, Inc. reported its financial results for the three months and year ended December 31, 2025, indicating the company's operational performance during this period.
The press release provides details on the company's revenue, profitability, and other key metrics, which investors can use to assess the company's financial health and future prospects.
Investors should review the full press release and financial statements to understand the company's overall business performance and any significant changes or events that occurred during the reported period.

Filed: 2026-01-13

Avanos Medical, Inc. is presenting at the JP Morgan Healthcare Conference on January 13, 2026, which could provide investors with insights into the company's strategic direction and growth plans.
The company's financial performance and future outlook will likely be a key focus of the presentation, which could impact investor sentiment.
Investors should watch for any updates or guidance related to Avanos Medical's product pipeline, regulatory approvals, or market expansion initiatives.

Other reports for AVANOS MEDICAL, INC.

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.